Moderna's (MRNA) BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. QCOM
2. MU
3. HTZ
4. FDX
5. CBRS
6. USO
7. SPY
8. KBH
9. LAES
10. HON

Go back to Moderna's (MRNA) BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

November 14, 2022 7:01 AM EST

In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273

Results build upon data recently published in the New England Journal of Medicine that confirmed superiority of the Company's BA.1 bivalent vaccine, mRNA-1273.214, neutralizing titers against multiple Omicron variants compared to a booster dose of mRNA-1273

Both of the Company's updated bivalent boosters (mRNA-1273.214 and mRNA-1273.222) showed neutralizing titers against BQ.1.1, an emerging threat globally, in an exploratory analysis

Safety and... More